Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Joseph A. de Leo

13 papers in the library · 179 citations · publishing 2020-2025

Papers

Integration in Psychedelic-Assisted Treatments: Recurring Themes in Current Providers’ Definitions, Challenges, and Concerns

Journal of Humanistic Psychology April 2, 2022 Mitch Earleywine, Fiona Low, Carmen Lau et al. 47 citations

Integration therapy, a key part of psychedelic-assisted treatment, helps people make sense of their psychedelic experiences after the drug's effects wear off. In interviews with 30 integration therapists, 19 themes emerged reliably. Therapists commonly defined integration as a bridge between the psychedelic experience and daily life, expressed concern about nonresponsive clients, and worried about the commercialization of psychedelic psychotherapy. They viewed integration as a process that starts before substance use, never ends, makes sense of the experience, creates behavioral change, is personalized, and makes the individual whole. Many also discussed client resistance, unrealistic expectations, power differentials, the need for connections to other providers, and self-care. The findings may help standardize integration therapy and inform future research.

How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression?

Journal of Psychoactive Drugs March 23, 2022 Mitch Earleywine, Fiona Low, Brianna R. Altman et al. 31 citations

People with depressive symptoms consider it somewhat important that guides in psilocybin-assisted therapy have personally used psilocybin. In a survey of over 800 MTurk respondents with depressive symptoms, ratings for the importance of a guide who had used psilocybin exceeded the "somewhat important" level (50 on a 0–100 scale) and were higher than ratings for other guide qualities and for a cognitive behavioral therapist who shared demographics, had depression experience, or received personal therapy. People of color and those with prior therapy gave even higher importance ratings. Participants listed similar desired qualities—proper training and empathy—for both psilocybin guides and CBT therapists. The findings suggest that guides who have used psilocybin and inform clients might enhance therapy's antidepressant effects for some clients.

Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials.

Journal of Psychoactive Drugs January 1, 2023 Zachary Herrmann, Mitch Earleywine, Joseph A. de Leo et al. 19 citations

Subjective responses to psychedelic drugs, such as mystical experiences and oceanic boundlessness, often correlate with therapeutic improvements in conditions like treatment-resistant depression, end-of-life anxiety, and substance use disorders. Measuring these responses is challenging; several scales show good reliability and factor structure, but samples are often small and self-selected. This review examines the psychometric properties of widely used scales and their links to treatment outcomes. Challenging experiences, psychological insight, and emotional breakthroughs also show promise, though replication is needed. A collaborative approach to data collection on subjective reactions in therapeutic settings could help predict improvement across conditions.

Ketamine-Assisted Psychotherapy Provides Lasting and Effective Results in the Treatment of Depression, Anxiety, and Post-Traumatic Stress Disorder at 3 and 6 Months: Findings from a Large Retrospective Effectiveness Study.

Psychedelic medicine (New Rochelle, N.Y.) June 1, 2024 Ryan Yermus, John Bottos, Nathan Bryson et al. 13 citations

Ketamine-assisted psychotherapy (KAP) produces sustained reductions in anxiety, depression, and PTSD symptoms lasting up to 5 months after the last session. In a retrospective study of adults with treatment-resistant major depressive disorder, generalized anxiety disorder, or PTSD who received KAP across 11 North American clinics, large treatment effects were detected at 3 months (Cohen's d = 0.75-0.86) and sustained at 6 months (d = 0.61-0.73). Case reductions ranged from 39% to 41% at 3 months and 29% to 37% at 6 months. However, high attrition rates (82% at 3 months, 95% at 6 months) may limit validity of the results.

Psychedelic-assisted psychotherapy for depression: How dire is the need? How could we do it?

Journal of Psychedelic Studies June 1, 2020 Mitch Earleywine, Joseph A. de Leo 12 citations

Antidepressant medications alone help only one in four patients and rarely outperform placebos, while psychotherapies yield better outcomes and combining both helps only 65% of clients who complete treatment. Psychedelics may improve depression through mechanisms overlapping with psychotherapy and some novel ones, suggesting their combination could work very well. Subjective experiences during psychedelic sessions correlate with improvement, so guiding clients to focus on targeted thoughts and feelings could enhance outcomes. Clinical trials of psychedelic-assisted, empirically supported treatment with guided sessions are needed, including preparatory, administration, integration, and follow-up components for maximum impact.

Expectancies for Cannabis-Induced Emotional Breakthrough, Mystical Experiences and Changes in Dysfunctional Attitudes: Perceptions of the Potential for Cannabis-Assisted Psychotherapy for Depression

Cannabis July 11, 2022 Mitch Earleywine, Maha N. Mian, Brianna R. Altman et al. 11 citations

People who use cannabis expect that a cannabis-assisted psychotherapy session, modeled on psychedelic-assisted psychotherapy, would reduce depression. Over 500 participants in each of two studies imagined such a session and reported expected antidepressant effects. Expected reductions in depression were linked to anticipated psychedelic-like subjective experiences, such as mystical-type feelings, and also to expected changes in dysfunctional attitudes—a separate pathway that resembles how cognitive therapy works. These findings support calls for clinical trials of cannabis-assisted psychotherapy and indicate that users anticipate it would work through mechanisms similar to both psychedelics and cognitive therapy.

Cognitive Behavioral Therapy, Ketamine, and Combination Treatment for Depression: Impressions of Credibility in Participants with Self-Reported Depressive Symptoms

Journal of Psychoactive Drugs April 20, 2021 M. Earleywine, Brianna R. Altman, Joseph A. de Leo 8 citations

People with depressive symptoms find a combination of ketamine and cognitive behavioral therapy (CBT) as credible as CBT alone, and both are seen as more credible than ketamine alone. Those who have had psychotherapy before tend to view ketamine as less credible. Depression severity does not relate to credibility ratings. The findings suggest that potential clients are cautious about ketamine despite media attention, and that providing balanced treatment descriptions may reveal important credibility information.

An examination of internal family systems interventions for trauma with implications for ethical psychedelic-assisted treatment

Journal of Psychedelic Studies March 5, 2024 Mitch Earleywine, Alyssa B. Oliva, Joseph A. de Leo et al. 6 citations

Internal Family Systems (IFS) therapy, which views the mind as composed of multiple subpersonalities or 'parts' shaped by trauma, has gained popularity, particularly in psychedelic-assisted treatments. However, outcome data for applying IFS to post-traumatic stress disorder are limited, and its theoretical assumptions are difficult to test. The model's appeal highlights a problem with how empirically supported treatments are perceived. Ethical recommendations for presenting IFS include providing detailed psychoeducation about evidence-based treatments, being candid about the experimental nature of alternatives, monitoring progress, and watching for harm. Drawing on IFS's appealing features to improve perceptions of validated treatments may attract more clients and reduce dropout while awaiting empirical evidence.

Expectancies for Subjective and Antidepressant Effects in Psilocybin Users

Journal of Humanistic Psychology September 22, 2023 Mitch Earleywine, Maha N. Mian, Joseph A. de Leo 5 citations

Expectations about psychedelics are understudied despite their powerful subjective effects. In over 500 people who have used psilocybin, expectancies about antidepressant effects correlated with specific subjective experiences—mystical experiences, ego dissolution, and emotional breakthrough—that previous work linked to depression improvement. Current depressive symptoms, ego dissolution, and emotional breakthrough each predicted unique variance in expected antidepressant effects, but mystical experience expectancies did not. Demographic factors and general hallucinogen involvement showed only weak correlations. These findings suggest that psilocybin users hold relevant expectancies about subjective and antidepressant effects, which could influence treatment outcomes and deserve monitoring in clinical trials.

Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression

Journal of Psychoactive Drugs January 3, 2022 Brianna R. Altman, Mitch Earleywine, Joseph A. de Leo 4 citations

People with depressive symptoms view cognitive-behavioral therapy (CBT) as more credible than psilocybin-assisted therapy (PAT). In a study of 803 adults recruited from Amazon's MTurk, participants read descriptions of each therapy and rated their credibility. Those with prior therapy experience rated CBT higher than those without. Men and individuals who had used hallucinogens rated PAT more favorably than women and non-users. Other demographic and clinical factors explained little of the variation in credibility ratings. The findings suggest that potential clients are cautious about PAT, and researchers and clinicians should consider patients' treatment beliefs as possible predictors of outcomes.

Client treatment preferences in psychedelic-assisted therapy for depression in participants with depressive symptoms

Journal of Psychedelic Studies July 11, 2024 Alyssa B. Oliva, Mitch Earleywine, Fiona Low et al.

In a survey of 635 adults in the United States, the importance people place on having a therapist of the same gender or same race differs by the type of therapy and by the participant's own race and gender. For both cognitive behavioral therapy (CBT) and psychedelic-assisted therapy (PAT), racial and ethnic minority participants and female participants rated a same-gender practitioner as more important than did White or male participants. A same-gender CBT therapist was rated as more important than a same-gender PAT guide.

Intentional Choices of Metaphors for Psychedelic-Assisted Therapy

Cognitive and Behavioral Practice April 1, 2025 M. Earleywine, Henry A MacConnel, Joseph A. de Leo

Metaphors used in psychedelic-assisted therapy (PAT) shape client expectations and outcomes, yet few publications address their deliberate use within a cognitive-behavioral framework. Common metaphors like journeys, brain rewiring, and medicines may not suit all clients or align with learning-focused interventions. This paper introduces baseball's "batting practice" as an alternative metaphor, emphasizing autonomy, agency, responsibility, and the incremental skill-building nature of PAT. Depicting the therapist as a coach reimagines therapy as active engagement, ongoing effort, gradual improvements, and periods of progress and stagnation, paralleling integration processes. The metaphor highlights process over outcomes, persistence, patience, mindfulness, and teamwork. Potential shortcomings are noted to encourage flexibility and collaborative metaphor selection for optimizing outcomes in psychedelic-assisted CBT.